Press Releases

Date Headline
4/13/2021
Zymeworks to Present at Bloom Burton Healthcare Conference
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conferencetaking place April 20-21,  Continue Reading
4/10/2021
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
 Summary
Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce   complement dependent cytotoxicity ProTECT™ (PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting), the first conditionally-active antibody technology that  Continue Reading
3/10/2021
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR)  Continue Reading
2/24/2021
Zymeworks Reports 2020 Year-End Financial Results
 Summary
Download the PDF version PDF Format (opens in new window) VANCOUVER, Canada--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a  Continue Reading
2/10/2021
Zymeworks to Participate in Upcoming Investor Conferences and Events
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.  Continue Reading
2/9/2021
Zymeworks Expands Commercial Team and Creates New R&D Role
 Summary
Download the PDF version PDF Format (opens in new window) James Priour promoted to Chief Commercial Officer, added to Zymeworks’ Executive Committee John Babcook recognized as Distinguished Fellow VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc.  Continue Reading
1/27/2021
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
 Summary
Active drug with multiple confirmed responses and stable disease observed in several tumor types Differentiated safety profile with the majority of adverse events being grade 1 or 2 Expansion cohorts open and enrolling patients at 2.5 mg/kg once every three weeks Maximum tolerated dose not  Continue Reading
1/15/2021
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
 Summary
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc.  Continue Reading
1/11/2021
Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities. “2020 was a leap forward for our lead clinical  Continue Reading
1/7/2021
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39 th  Annual J.P. Morgan Healthcare Conference.  Continue Reading
Displaying 11 - 20 of 20
Copyright 2021 , Zymeworks Inc.